Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

ACR/ARHP Annual Meeting 2012: New Research Into Stem Cell Therapy and Drugs May Lead to Breakthrough Treatments for Osteoarthritis

Susan Bernstein  |  Issue: February 2013  |  February 1, 2013

Stem cells may be used one day to mend or treat OA-damaged joints, or to create models that help test potential disease-modifying drugs or figure out how OA occurs, Dr. Tuan said. “The cells are really the true tissue engineers. We are just the coaches and cheerleaders,” he concluded.

OA Starting at an Earlier Age

People are getting OA earlier in many developed countries, said David Hunter, MD, PhD, a rheumatologist at Royal North Shore Hospital in Sydney, Australia. The median age of diagnosis is now around 56 years of age, he said. OA diagnoses will likely increase due to several factors. “We are all getting bigger!” he said. “Similarly, joint injury is also one of the biggest drivers for people getting this disease, along with obesity. We are not doing anything about these problems and we need to.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Most of his OA patients want to delay or avoid surgery, Dr. Hunter said. Weight reduction to reduce load on joints, preventing OA, or slowing progression should be the first line of defense. Later, palliative strategies like analgesia or, if necessary, arthroplasty can be implemented, Dr. Hunter said.

Drugs now in development that are attracting attention for OA include antinerve growth factor antibodies like tanezumab (although phase III trials to treat OA pain were halted when some participants required joint replacements due to rapidly progressing disease despite symptom relief); bisphosphonates like zoledronic acid; calcitonin; and strontium ranelate. In the future, researchers will focus more on biomarkers that may reveal what patients are most at risk for OA, Dr. Hunter said. These genetic clues, the subject of research efforts by groups like the Biomarkers Consortium of the Foundation of the National Institutes of Health, may indicate signs of OA years before symptoms develop or radiographic evidence is detectable, Dr. Hunter said.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Most of all, rheumatologists must focus on the whole patient in OA, as well as the whole joint, Dr. Hunter concluded. “We are not just interested in cartilage, but OA’s effects on bone, muscle, synovium, and also cartilage. If we do, we are likely to have much more meaningful results,” he said.


Susan Bernstein is a freelance medical journalist based in Atlanta.

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsMeeting ReportsOsteoarthritis and Bone DisordersResearch Rheum Tagged with:OsteoarthritisResearchStem CellsTreatment

Related Articles

    Rheumatologist Marc C. Hochberg, MD, MPH, Advances Epidemiology Through Collaborative Ties

    May 1, 2014

    Accomplished physician noted for research in gout, osteoarthritis etiology; characterizing therapeutic responsiveness in disease states; inspiring teamwork among rheumatologists

    Cellular Therapy of Autoimmune Disease

    November 1, 2008

    Is a novel treatment breakthrough on the horizon?

    Basics of Biologic Joint Reconstruction

    April 6, 2012

    For young patients especially, this can delay knee replacement and provide better outcomes.

    New Therapeutics for Osteoarthritis May Be in Sight

    April 1, 2015

    Overview of OA pathogenesis, recent discoveries suggest new treatment strategies are possible

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences